Kenichiro Kudo1, Katsuyuki Hotta2,3, Akihiro Bessho4, Naoyuki Nogami5, Toshiyuki Kozuki5, Shoichi Kuyama6, Koji Inoue7, Shingo Harita8, Toshiaki Okada8, Kenichi Gemba9, Masanori Fujii10, Nagio Takigawa11, Naohiro Oda1, Mitsune Tanimoto12, Katsuyuki Kiura1. 1. Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. 2. Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. khotta@okayama-u.ac.jp. 3. Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan. khotta@okayama-u.ac.jp. 4. Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan. 5. Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, Matsuyama, Japan. 6. Department of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni, Japan. 7. Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan. 8. Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan. 9. Department of Respiratory Medicine, NHO Fukuyama Medical Center, Fukuyama, Japan. 10. Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan. 11. Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. 12. Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan.
Abstract
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy. METHODS: We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined. RESULTS: Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %; p = 0.077). CONCLUSION: Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy.
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy. METHODS: We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined. RESULTS: Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %; p = 0.077). CONCLUSION: Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy.
Authors: Hannah R Wardill; Raymond J Chan; Alexandre Chan; Dorothy Keefe; Samuel P Costello; Nicolas H Hart Journal: Support Care Cancer Date: 2022-03-10 Impact factor: 3.359
Authors: Youngjoo Lee; Ki Hyeong Lee; Geon Kook Lee; Soo-Hyun Lee; Kun Young Lim; Jungnam Joo; Yun Jung Go; Jin Soo Lee; Ji-Youn Han Journal: Cancer Res Treat Date: 2017-01-13 Impact factor: 4.679